OA07069A - Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. - Google Patents
Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.Info
- Publication number
- OA07069A OA07069A OA57657A OA57657A OA07069A OA 07069 A OA07069 A OA 07069A OA 57657 A OA57657 A OA 57657A OA 57657 A OA57657 A OA 57657A OA 07069 A OA07069 A OA 07069A
- Authority
- OA
- OAPI
- Prior art keywords
- ricin
- preparation
- cancer drugs
- drugs containing
- chain associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8107596A FR2504010B1 (fr) | 1981-04-15 | 1981-04-15 | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
OA07069A true OA07069A (fr) | 1984-01-31 |
Family
ID=9257448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA57657A OA07069A (fr) | 1981-04-15 | 1982-04-13 | Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. |
Country Status (30)
Country | Link |
---|---|
US (1) | US4414148A (xx) |
EP (1) | EP0063988B1 (xx) |
JP (1) | JPS57179124A (xx) |
KR (1) | KR880001045B1 (xx) |
AR (1) | AR228394A1 (xx) |
AT (1) | ATE17653T1 (xx) |
AU (1) | AU556641B2 (xx) |
CA (1) | CA1195248A (xx) |
CZ (1) | CZ256482A3 (xx) |
DD (1) | DD204849A5 (xx) |
DE (1) | DE3268752D1 (xx) |
DK (1) | DK159277C (xx) |
EG (1) | EG15718A (xx) |
ES (1) | ES8303918A1 (xx) |
FI (1) | FI76693C (xx) |
FR (1) | FR2504010B1 (xx) |
GR (1) | GR69199B (xx) |
HU (1) | HU188314B (xx) |
IE (1) | IE53009B1 (xx) |
IL (1) | IL65441A0 (xx) |
MA (1) | MA19429A1 (xx) |
NO (1) | NO154905C (xx) |
NZ (1) | NZ200302A (xx) |
OA (1) | OA07069A (xx) |
PH (1) | PH20846A (xx) |
PL (1) | PL135800B1 (xx) |
PT (1) | PT74741B (xx) |
SU (1) | SU1329604A3 (xx) |
YU (1) | YU83082A (xx) |
ZA (1) | ZA822528B (xx) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5843926A (ja) * | 1981-09-08 | 1983-03-14 | Suntory Ltd | 選択性制癌剤 |
FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
ATE25197T1 (de) * | 1982-05-12 | 1987-02-15 | Harvard College | Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung. |
US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
JPS5990052A (ja) * | 1982-11-16 | 1984-05-24 | Katsu Taniguchi | モノクロ−ナル特異抗体を用いたメラノ−マ診断薬 |
US4916213A (en) * | 1983-02-22 | 1990-04-10 | Xoma Corporation | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof |
US4591572A (en) * | 1983-04-01 | 1986-05-27 | Sloan-Kettering Institute For Cancer Research | Pigmentation associated, differentiation antigen of human melanoma and autologous antibody |
JPS59186924A (ja) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
GB2142428A (en) * | 1983-06-23 | 1985-01-16 | Erba Farmitalia | Adenocarcinoma related antigenic determinants and antibodies specific thereto |
FR2547731A1 (fr) * | 1983-06-27 | 1984-12-28 | Centre Nat Rech Scient | Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
FR2570278B1 (fr) * | 1984-09-14 | 1987-02-13 | Pasteur Institut | Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise |
AU585940B2 (en) * | 1984-09-25 | 1989-06-29 | Xoma Corporation | Lectin immunotoxins |
EP0232447A1 (en) * | 1986-02-13 | 1987-08-19 | Xoma Corporation | Lectin immunotoxins |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
FR2573656B1 (fr) * | 1984-11-29 | 1987-02-27 | Sanofi Sa | Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose |
US4851510A (en) * | 1984-11-30 | 1989-07-25 | Wadley Technologies, Inc. | Monoclonal antibodies to novel melanoma-associated antigens |
AT384549B (de) * | 1985-01-08 | 1987-11-25 | Strasser Engelbert | Verfahren zur herstellung einer vaccine |
US5256413A (en) * | 1985-01-08 | 1993-10-26 | The General Hospital Corporation | Method and use for site-specific activation of substances |
FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
US4744981A (en) * | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
AU609380B2 (en) * | 1985-11-29 | 1991-05-02 | Consolidated Pharmaceuticals Limited | Ricin-antibody conjugates |
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
US4689401A (en) * | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
USRE38008E1 (en) | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US5009995A (en) * | 1986-10-27 | 1991-04-23 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to melanoma cells |
US5582862A (en) | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
US5811265A (en) * | 1988-08-19 | 1998-09-22 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
US5609869A (en) * | 1988-08-19 | 1997-03-11 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
IE910820A1 (en) * | 1990-03-22 | 1991-09-25 | Sloan Kettering Inst Cancer | Gp75 as a tumor vaccine for melanoma |
NZ237688A (en) * | 1990-04-19 | 1993-01-27 | Res Dev Foundation | Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment |
US5981194A (en) * | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
EP0937146A2 (en) * | 1996-09-20 | 1999-08-25 | The General Hospital Corporation | Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
US6869604B1 (en) * | 1998-03-27 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant anti-tumor RNAse |
US6852318B1 (en) | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
EP1075277B2 (en) * | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
US20020155507A1 (en) | 2000-10-06 | 2002-10-24 | Bruchez Marcel P. | Cells having a spectral signature, and methods of preparation and use thereof |
EP2381116A1 (en) | 2000-11-16 | 2011-10-26 | California Institute of Technology | Apparatus and methods for conducting assays and high throughput screening |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
US6955888B2 (en) * | 2001-06-11 | 2005-10-18 | Xenoport | Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter |
CN1555268B (zh) * | 2001-07-17 | 2013-04-03 | 研究发展基金会 | 含促调亡蛋白质的治疗剂 |
WO2003048295A1 (en) | 2001-11-30 | 2003-06-12 | Fluidigm Corporation | Microfluidic device and methods of using same |
US20030158254A1 (en) * | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
US20030158089A1 (en) * | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Administrative agents via the SMVT transporter |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20030228619A1 (en) * | 2002-06-10 | 2003-12-11 | Xenoport, Inc. | Peptide nucleic acids as tags in encoded libraries |
CA2488858A1 (en) * | 2002-06-12 | 2003-12-24 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
PL217626B1 (pl) | 2002-07-18 | 2014-08-29 | Helix Biopharma Corp | Kompozycja farmaceutyczna do zastosowania w leczeniu raka |
US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
EP2340890B1 (en) | 2003-04-03 | 2016-10-19 | Fluidigm Corporation | Method of performimg digital PCR |
WO2006102264A1 (en) | 2005-03-18 | 2006-09-28 | Fluidigm Corporation | Thermal reaction device and method for using the same |
KR20070007086A (ko) | 2004-02-02 | 2007-01-12 | 암브룩스, 인코포레이티드 | 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도 |
BRPI0512235A (pt) | 2004-06-18 | 2008-02-19 | Ambrx Inc | polipeptìdeos ligadores de antìgenos e seus usos |
CA2569381A1 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
US20090208932A1 (en) * | 2004-11-16 | 2009-08-20 | Edouard Collins Nice | Methods Of Detecting An Analyte In A Sample |
GB2438760A (en) | 2004-12-22 | 2007-12-05 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
AU2005319518B2 (en) * | 2004-12-22 | 2010-09-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
CA2594557C (en) | 2004-12-22 | 2016-04-26 | Ambrx, Inc. | Modified human growth hormone |
NZ555386A (en) * | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
CA3005835C (en) | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US20060171919A1 (en) * | 2005-02-01 | 2006-08-03 | Research Development Foundation | Targeted polypeptides |
SG165353A1 (en) * | 2005-06-03 | 2010-10-28 | Ambrx Inc | Improved human interferon molecules and their uses |
CN102703446B (zh) * | 2005-08-18 | 2014-05-28 | Ambrx公司 | tRNA组合物和其用途 |
NZ567234A (en) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
WO2007059312A2 (en) | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
CA2631491C (en) * | 2005-12-14 | 2015-02-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US9133495B2 (en) * | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
AU2007292903B2 (en) * | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
CN101511856B (zh) * | 2006-09-08 | 2016-01-20 | Ambrx公司 | 脊椎动物细胞中抑制因子trna的转录 |
CN101678090B (zh) * | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
NZ580686A (en) * | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
EP2348052A3 (en) | 2007-09-17 | 2011-10-26 | The Regents of The University of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
CN108129573B (zh) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
ES2632504T3 (es) | 2007-11-20 | 2017-09-13 | Ambrx, Inc. | Polipéptidos de insulina modificados y sus usos |
NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
IL198123A0 (en) | 2008-04-18 | 2009-12-24 | Snecma Propulsion Solide | A heat treatment oven with inductive heating |
WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
NZ600382A (en) * | 2008-07-23 | 2013-11-29 | Ambrx Inc | Modified bovine G-CSF polypeptides and their uses |
WO2010036964A2 (en) | 2008-09-26 | 2010-04-01 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
ES2660000T3 (es) | 2008-09-26 | 2018-03-20 | Ambrx, Inc. | Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales |
EP2393470B1 (en) | 2009-02-06 | 2017-04-05 | The Regents of The University of California | Calcium-binding agents induce hair growth and/or nail growth |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
PL2605789T3 (pl) | 2010-08-17 | 2019-11-29 | Ambrx Inc | Zmodyfikowane polipeptydy relaksyny i ich zastosowania |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
US9090691B2 (en) | 2010-09-15 | 2015-07-28 | Applied Molecular Transport Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
EP2621523B1 (en) | 2010-09-29 | 2017-08-09 | UTI Limited Partnership | Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
AU2012229156A1 (en) | 2011-03-11 | 2013-10-31 | Board Of Regents Of The University Of Nebraska | Biomarker for coronary artery disease |
US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
DK3170821T3 (da) | 2011-05-27 | 2021-10-11 | Ambrx Inc | Sammensætninger som indeholder, fremgangsmåder som involverer, og anvendelser af ikke-naturlige aminosyrebundne dolastatinderivater |
KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
CN104470536A (zh) | 2012-03-03 | 2015-03-25 | 免疫基因公司 | 工程化的抗体-干扰素突变体融合分子 |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
CN108727466B (zh) | 2012-06-07 | 2023-04-28 | Ambrx公司 | 前列腺特异性膜抗原抗体药物结合物 |
KR20150023729A (ko) | 2012-06-14 | 2015-03-05 | 암브룩스, 인코포레이티드 | 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체 |
WO2013192360A1 (en) | 2012-06-19 | 2013-12-27 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
WO2015063616A2 (en) | 2013-11-04 | 2015-05-07 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
FR3018526B1 (fr) | 2014-03-14 | 2021-06-11 | Herakles | Installation de densification cvi comprenant une zone de prechauffage a forte capacite |
CN106470707A (zh) | 2014-05-07 | 2017-03-01 | 应用分子运输有限责任公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
CA2965502A1 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
KR20180011135A (ko) | 2015-05-06 | 2018-01-31 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
BR112018009004A8 (pt) | 2015-11-03 | 2019-02-26 | Ambrx Inc | conjugados anti-cd3-folato e seus usos |
WO2017095823A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
US20190161523A1 (en) | 2016-04-12 | 2019-05-30 | Blaze Bioscience, Inc. | Methods of treatment using chlorotoxin conjugates |
CA3021011A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
WO2018089807A2 (en) | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
JP2020503857A (ja) | 2016-12-12 | 2020-02-06 | セファイド | 自動反応カートリッジにおける統合化イムノpcr及び核酸分析 |
WO2018129200A2 (en) | 2017-01-05 | 2018-07-12 | The Regents Of The University Of California | Pac1 receptor agonists (maxcaps) and uses thereof |
MX2019008449A (es) | 2017-02-08 | 2019-09-09 | Bristol Myers Squibb Co | Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos. |
SG11202009925PA (en) | 2018-03-08 | 2020-11-27 | Applied Molecular Transport Inc | Toxin-derived delivery constructs for oral delivery |
CA3093386A1 (en) | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
WO2019191728A1 (en) | 2018-03-29 | 2019-10-03 | Ambrx, Inc. | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
CA3110647A1 (en) | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
EP3849614B1 (en) | 2018-09-11 | 2023-12-20 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
SG11202108254YA (en) | 2019-02-12 | 2021-08-30 | Ambrx Inc | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
CA3150859A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
IL300528A (en) | 2020-08-07 | 2023-04-01 | Fortis Therapeutics Inc | Immune conjugates targeting cd46 and methods of using them |
EP4199968A1 (en) | 2020-08-20 | 2023-06-28 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
IL307282A (en) | 2021-04-03 | 2023-11-01 | Ambrx Inc | Antidote conjugates against HER2 and their applications |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
-
1981
- 1981-04-15 FR FR8107596A patent/FR2504010B1/fr not_active Expired
-
1982
- 1982-04-01 MA MA19633A patent/MA19429A1/fr unknown
- 1982-04-06 IE IE815/82A patent/IE53009B1/en not_active IP Right Cessation
- 1982-04-06 IL IL65441A patent/IL65441A0/xx not_active IP Right Cessation
- 1982-04-07 CA CA000400606A patent/CA1195248A/en not_active Expired
- 1982-04-08 AU AU82510/82A patent/AU556641B2/en not_active Ceased
- 1982-04-09 GR GR67862A patent/GR69199B/el unknown
- 1982-04-09 CZ CS822564A patent/CZ256482A3/cs unknown
- 1982-04-09 AT AT82400651T patent/ATE17653T1/de not_active IP Right Cessation
- 1982-04-09 EP EP82400651A patent/EP0063988B1/fr not_active Expired
- 1982-04-09 DE DE8282400651T patent/DE3268752D1/de not_active Expired
- 1982-04-12 AR AR289058A patent/AR228394A1/es active
- 1982-04-13 NO NO821198A patent/NO154905C/no unknown
- 1982-04-13 PT PT74741A patent/PT74741B/pt not_active IP Right Cessation
- 1982-04-13 OA OA57657A patent/OA07069A/xx unknown
- 1982-04-14 EG EG205/82A patent/EG15718A/xx active
- 1982-04-14 US US06/368,434 patent/US4414148A/en not_active Expired - Fee Related
- 1982-04-14 YU YU00830/82A patent/YU83082A/xx unknown
- 1982-04-14 SU SU823427002A patent/SU1329604A3/ru active
- 1982-04-14 DK DK167482A patent/DK159277C/da not_active IP Right Cessation
- 1982-04-14 FI FI821304A patent/FI76693C/fi not_active IP Right Cessation
- 1982-04-14 NZ NZ200302A patent/NZ200302A/en unknown
- 1982-04-14 DD DD82238983A patent/DD204849A5/de not_active IP Right Cessation
- 1982-04-14 ZA ZA822528A patent/ZA822528B/xx unknown
- 1982-04-14 ES ES511433A patent/ES8303918A1/es not_active Expired
- 1982-04-14 HU HU821135A patent/HU188314B/hu not_active IP Right Cessation
- 1982-04-15 PH PH27142A patent/PH20846A/en unknown
- 1982-04-15 KR KR8201664A patent/KR880001045B1/ko active
- 1982-04-15 PL PL1982235981A patent/PL135800B1/pl unknown
- 1982-04-15 JP JP57061857A patent/JPS57179124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA07069A (fr) | Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. | |
OA07103A (fr) | Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant. | |
DZ312A1 (fr) | Interferons et procédé pour leur préparation. | |
IT1150682B (it) | Procedimento per la produzione di sostanze prodotte da cellule,particolarmente di anticorpi e simili | |
FR2516794B1 (fr) | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique | |
FI822964L (fi) | Med laosanordning foersedd icke-metallisk biologiskt anpassbar blodkaerlsklaemma | |
FR2344839A1 (fr) | Composition, detecteur et methode pour la recherche d'un composant dans un echantillon | |
OA05638A (fr) | Nouveaux agents anthelminthiques et procédés pour leur préparation. | |
FR2434201B1 (fr) | Procede et necessaire de determination et de dosage immunologique d'une substance par creation d'un micro-environnement concentre | |
NO870893D0 (no) | Apparat for behandling av smeltet metall. | |
MC1418A1 (fr) | 2,4-diamino-pyrimidines,leur preparation et medicaments contenant ces substances | |
FR2500166B1 (fr) | Reactif et procede pour dosage immunologique d'antigenes | |
OA08444A (fr) | Nouveaux céphèmes et procédés pour leur préparation. | |
OA07172A (fr) | Nouvelles thiazolidinediones, leur procédé de production et préparation pharmaceutique les contenant. | |
IT8719086A0 (it) | Immunoglobulina iniettabile per via endovenosa con un elevato titolo di anticorpi contro il virussinciziale respiratorio, procedimento per la sua produzione e preparato farmaceutico che lo contiene. | |
OA05575A (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation ainsi que les compositions les contenant. | |
OA09190A (fr) | "Procédés de préparation de dérivés d'acides benzocycloalcényl dihydroxy alcanoïques et de médicaments les contenant". | |
FR2527928B1 (fr) | Procede de preparation d'anticorps monoclonaux conjugues avec un chelate metallique et solution les contenant | |
OA04772A (fr) | Nouveaux dérivés d'imidazolidine utiles à la lutte contre les parasites et procédé pour leur préparation. | |
OA07341A (fr) | Nouveaux oximéthers, procédé pour leur préparation, agents contenant les nouveaux oximéthers et leur application. | |
IL77990A (en) | Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same | |
FR2503713B1 (fr) | 2,3-di-substitue-5,6-dihydro-imidazo-(2,1-b) thiazoles, procede pour leur preparation et agents anti-inflammatoires les contenant | |
NL186860C (nl) | N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten. | |
PT77767B (fr) | Procede de preparation de 3',5'-diarabinosides et de compositi-ons pharmaceutiques les contenant | |
OA04266A (fr) | Procédé et dispositif pour la préparation de pâtes carbonées, destinées à la fabrication d'électrodes. |